ArticleZhonghua zhong liu za zhi [Chinese journal of oncology]2021
[Chinese expert consensus on lipid management in patients with malignancy].
Article in Zhonghua zhong liu za zhi [Chinese journal of oncology], 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05976893 (Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer), which is not on this map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer
Who cites it
4 citing papers in PubMed.
- L-shaped association of low-density lipoprotein cholesterol with all-cause and cardiovascular mortality in cancer survivors: a population-based cohort study.Frontiers in cardiovascular medicine · 2025Article
- [Causal Relationship Between Components of Metabolic Syndrome and Endometrial Carcinoma].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Article
- Etiological relationship between lipid metabolism and endometrial carcinoma.Lipids in health and disease · 2023Review
- Postmenopausal Women with Breast, Endometrial, and Ovarian Cancers Have an Increased Risk for Cardiovascular Conditions prior to Active Endocrine Therapy.Oxidative medicine and cellular longevity · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Patients with malignant tumors are often combined with dyslipidemia, and dyslipidemia is associated with both malignant tumor disease and treatment. The expert group of the Integrative Cardio-Oncology Society of China Anti-Cancer Association summarized the incidence rate and characteristics of dyslipidemia in patients with malignant tumors, and the characteristics and mechanisms of dyslipidemia induced by common antineoplastic drugs, stratified the risk of dyslipidemia in antineoplastic drugs, then formulated the principles of dyslipidemia treatment and monitoring. This consensus refers to domestic and aboard research progress, combineds with China's clinical experience to formulate the corresponding prevention and treatment of dyslipidemia. The present consensus provides practical strategies for clinicians in the management of dyslipidemia in malignant tumors and promotes the management of dyslipidemia in malignant tumors in China.
Indexed as
Identifiers
34695894What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.